Abstract
Research in new treatments for schizophrenia continues. At the same time, increasing numbers of persons with schizophrenia receive their treatment almost exclusively in correctional settings. Though the literature continues to describe this phenomenon in clearer detail, many questions regarding the characteristics of these mentally disordered offenders and their unique treatment needs remain. Research targeting this growing subset of persons with schizophrenia is limited. Risk factors that lead the person with schizophrenia into the correctional system, and whether the offenders with schizophrenia actually differ from non-offenders in terms of their psychopharmacological needs are significant questions that remain unaddressed. Countertransference towards the offender remains a significant issue as well. Given the many limitations on research in this population, pharmacologic strategies for the offender population must be extrapolated from the non-offender population. Traditional depot neuroleptics continue to be underutilized in the treatment of this population. It is argued that both traditional and forthcoming atypical depot neuroleptics may be the best first line agents in this population.
Keywords: Schizophrenia, psychopharmacological, Countertransference, neuroleptics
Current Pharmaceutical Design
Title: Treatment Considerations in the Forensic Patient with Schizophrenia
Volume: 10 Issue: 18
Author(s): David C. Stone and David O. Niz
Affiliation:
Keywords: Schizophrenia, psychopharmacological, Countertransference, neuroleptics
Abstract: Research in new treatments for schizophrenia continues. At the same time, increasing numbers of persons with schizophrenia receive their treatment almost exclusively in correctional settings. Though the literature continues to describe this phenomenon in clearer detail, many questions regarding the characteristics of these mentally disordered offenders and their unique treatment needs remain. Research targeting this growing subset of persons with schizophrenia is limited. Risk factors that lead the person with schizophrenia into the correctional system, and whether the offenders with schizophrenia actually differ from non-offenders in terms of their psychopharmacological needs are significant questions that remain unaddressed. Countertransference towards the offender remains a significant issue as well. Given the many limitations on research in this population, pharmacologic strategies for the offender population must be extrapolated from the non-offender population. Traditional depot neuroleptics continue to be underutilized in the treatment of this population. It is argued that both traditional and forthcoming atypical depot neuroleptics may be the best first line agents in this population.
Export Options
About this article
Cite this article as:
Stone C. David and Niz O. David, Treatment Considerations in the Forensic Patient with Schizophrenia, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384079
DOI https://dx.doi.org/10.2174/1381612043384079 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sigma-2 Receptor Ligands: Neurobiological Effects
Current Medicinal Chemistry Psychopharmacological Interventions for Adolescents with Eating Disorders
Adolescent Psychiatry Motif Discovery in Speech: Application to Monitoring Alzheimer’s Disease
Current Alzheimer Research EDITORIAL [Hot Topic: Transthyretin: A Small Protein in the Big World of Amyloidoses (Guest Editors: Adriano Martinelli and Gabriella Ortore)]
Current Medicinal Chemistry Role of Brassinosteroid in Plant Adaptation to Abiotic Stresses and its Interplay with Other Hormones
Current Protein & Peptide Science Homology Modeling of Human Nicotinamide/Nicotinic Acid Mononucleotide Adenylyltransferase 2: Insights into Isoenzyme-Specific Differences Using Molecular Docking Simulatons
Letters in Drug Design & Discovery Macromolecular Bases of Antischistosomal Therapy
Current Topics in Medicinal Chemistry Melatonin and Synthetic Melatonergic Agonists: Actions and Metabolism in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Letters in Drug Design & Discovery Withdrawal Notice: A Rough Set Based Approach to Compute The Impact of Non-Academic Parameters on Academic Performance
Recent Advances in Computer Science and Communications Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews The Epidemiology of Adiposity and Dementia
Current Alzheimer Research Editorial (Thematic Issue: Psychogeriatrics: An Interdisciplinary Approach)
Current Psychopharmacology PredCSF: An Integrated Feature-Based Approach for Predicting Conotoxin Superfamily
Protein & Peptide Letters Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Alterations in Hepatic Lipid Metabolism, and their Relation to Dietary Macronutrients in Pediatric Nonalcoholic Fatty Liver Disease
Drug Metabolism Letters Adolescence and Borderline Behavior - Between Personality Development and Personality Disorder
Adolescent Psychiatry Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Mechanisms of the Blunting of the Sympatho-Adrenal Response: A Theory
Current Diabetes Reviews Recent Patents of Nanodevices for Single Cell Immunological Assays
Recent Patents on Nanotechnology